Form 4 for MLTX MoonLake Immunotherapeutics
Accepted 2024-02-23 00:00:00 ET · period of report 2024-02-21 · accession 0001213900-24-016544 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-02-23 | 2024-02-21 | MLTX | Santos da Silva Jorge | CEO, Dir | S - Sale | $55.27 | -1,125 | 3.11M | -0.0% | -$62.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A ordinary shares, par value $0.0001 per share | 2024-02-21 | S | D | 1,125 | $55.27 | 3,106,429 | D | — | — | (F2) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.025 to $55.33. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |